Oregon Public Employees Retirement Fund Has $5.80 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Oregon Public Employees Retirement Fund grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,826 shares of the medical instruments supplier’s stock after buying an additional 128 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Becton, Dickinson and Company were worth $5,802,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at approximately $27,000. OLD Point Trust & Financial Services N A acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at $29,000. Scarborough Advisors LLC bought a new stake in Becton, Dickinson and Company during the 4th quarter worth about $32,000. Rise Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $38,000. Finally, ICA Group Wealth Management LLC bought a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at about $42,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $236.29 on Thursday. The company’s 50-day moving average is $234.04 and its 200-day moving average is $236.04. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The firm has a market capitalization of $68.29 billion, a PE ratio of 52.05, a PEG ratio of 1.98 and a beta of 0.42. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $278.45.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. Becton, Dickinson and Company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.96 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 13.1 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 1.61%. The ex-dividend date of this dividend is Monday, September 9th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. The Goldman Sachs Group assumed coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective on the stock. Raymond James decreased their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Evercore ISI dropped their price target on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Finally, Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and a consensus target price of $279.50.

Insider Transactions at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 300 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.